Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) exon 20 insertions (ins) represent a challenging molecular alteration in advanced non-small cell lung cancer (NSCLC).
• Historically, EGFR exon 20 insertions were considered an
• undruggable target
• with platinum-pemetrexed chemotherapy as the standard upfront treatment.
• A small percentage of advanced NSCLC patients (1-2%) harbor this specific mutation.

Purpose of the Study:

• To provide an updated overview of recent findings and challenges in the molecular detection and therapeutic management of EGFR exon 20 insertion mutant advanced NSCLC.
• To highlight the emergence of targeted therapies for this patient population.
• To emphasize the importance of molecular screening in NSCLC.

Main Methods:

• Review of preliminary data from early-phase clinical trials on EGFR inhibitors.
• Analysis of regulatory approvals for amivantamab and mobocertinib.
• Discussion of next-generation sequencing (NGS)-based genotyping as a gold standard for molecular profiling.

Main Results:

• Pharmacological inhibition of EGFR exon 20 insertions is now possible, offering new treatment opportunities.
• Amivantamab and mobocertinib have received FDA approval in the US, and amivantamab is also approved in Europe for previously treated advanced NSCLC patients with EGFR exon 20 insertions.
• These approvals represent a significant breakthrough in lung cancer treatment.

Conclusions:

• Novel targeted therapies are transforming the treatment landscape for advanced NSCLC patients with EGFR exon 20 insertions.
• Optimizing molecular screening, particularly with NGS, is crucial for identifying eligible patients.
• Continued research is needed to address upcoming challenges in detection and management.